The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice

Leukemia

Volumn 16, Issue 12, 2002, Pages 2388-2394

  Lehne, G ^a   Sorensen D R ^a   Tjonnfjord G E ^a   Beiske, C ^a   Hagve, T A ^a   Rugstad, H E ^a   Clausen, O P F ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

In vivo; Leukemia; NOD SCID mice; P glycoprotein; PSC 833

Indexed keywords

AMIDE; ANTHRANILIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CYCLOSPORIN A; CYTOKINE; ELACRIDAR; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; PLACEBO; SPHINGOLIPID; STEROID; TARIQUIDAR; VALSPODAR; ZOSUQUIDAR;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG EFFECT; DRUG RETENTION; DRUG TOLERABILITY; ENZYME SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MITOSIS INHIBITION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; XENOTRANSPLANTATION;

EID: 0036939821     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402663     Document Type: Article

References (58)

1. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-171.
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-162.
3. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316: 1388-1393.
4. Mulder HS, Dekker H, Pinedo HM, Lankelma J. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Biochem Pharmacol 1995; 50: 967-974.
5. Chan HS, DeBoer G, Haddad G, Gallie BL, Ling V. Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am 1995; 9: 275-318.
6. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, Serra M. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995; 333: 1380-1385.
7. Marie JP, Zhou DC, Gurbuxani S, Legrand O, Zittoun R. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 1996; 32A: 1034-1038.
8. Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol 1994; 12: 2453-2459.
9. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996; 88: 1747-1754.
10. Raghu G, Park SW, Roninson IB, Mechetner EB. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 1996; 24: 1258-1264.
11. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996; 87: 507-517.
12. Bosch I, Dunussi-Joannopoulos K, Wu RL, Furlong ST, Croop J. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry 1997; 36: 5685-5694.
13. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-199.
14. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996; 32A: 1070-1081.
15. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 1991; 27: 1639-1642.
16. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595-4602.
17. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996; 56: 4171-4179.
18. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001; 61: 749-758.
19. Chauncey TR, Rankin C, Anderson JE, Chen I, Kopecky KJ, Godwin JE, Kalaycio ME, Moore DF, Shurafa MS, Petersdorf SH, Kraut EH, Leith CP, Head DR, Luthardt FW, Willman CL, Appelbaum FR. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617. Leuk Res 2000; 24: 567-574.
20. Baekelandt M, Lehne G, Trope CG, Szanto I, Pfeiffer P, Gustavssson B, Kristensen GB. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. J Clin Oncol 2001; 19: 2983-2993.
21. Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, Roe D, List AF. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol 2001; 19: 1589-1599.
22. Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19: 2975-2982.
23. Visani G, Milligan D, Leoni F, Chang J, Kelsey S, Marcus R, Powles R, Schey S, Covelli A, Isidori A, Litchman M, Piccaluga PP, Mayer H, Malagola M, Pfister C. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. Leukemia 2001; 15: 764-771.
24. Lehne G, Rugstad HE. Cytotoxic effect of the cyclosporin PSC 833 by inhibition of P-glycoprotein in multidrug resistant leukemia cells. Br J Cancer 1998; 78: 593-600.
25. Lehne G, De Angelis P, Clausen OP, Egeland T, Tsuruo T, Rugstad HE. Binding diversity of antibodies against external and internal epitopes of the multidrug resistance gene product P-glycoprotein. Cytometry 1995; 20: 228-237.
26. Rehbinder C, Baneux P, Forbes D, van Herck H, Nicklas W, Rugaya Z, Winkler G. FELASA recommendations for the health monitoring of mouse, rat, hamster, gerbil, guinea pig and rabbit experimental units. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health accepted by the FELASA Board of Management, November 1995. Lab Anim 1996; 30: 193-208.
27. Bergan S, Rugstad HE, Stokke O, Bentdal O, Froysaker T, Bergan A. Cyclosporine A monitoring in patients with renal, cardiac, and liver transplants: a comparison between fluorescence polarization immunoassay and two different RIA methods. Scand J Clin Lab Invest 1993; 53: 471-477.
28. Scott MG, Hock KG, Crimmins DL, Fracasso PM. HPLC method for monitoring SDZ PSC 833 in whole blood. Clin Chem 1997; 43: 505-510.
29. Arguello F, Sterry JA, Zhao YZ, Alexander MR, Shoemaker RH, Cohen HJ. Two serologic markers to monitor the engraftment, growth, and treatment response of human leukemias in severe combined immunodeficient mice. Blood 1996; 87: 4325-4332.
30. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 2000; 1: 85-99.
31. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 1997; 36: 11169-11178.
32. Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou JP. Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J 1998; 12: 101-109.
33. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug- resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998; 95: 7024-7029.
34. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999; 93: 1075-1085.
35. Pallis M, Russell N. P-glycoprotein expression is associated with resistance to spontaneous in vitro apoptosis in AML. Leukemia 1999; 13: 1468-1469.
36. Pallis M, Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 2000; 95: 2897-2904.
37. List AF, Glinsmann-Gibson B, Heaton R, Schlegel S, Guzman M, Futscher B. Cyclosporines inhibit interleukin-1-beta sectretion by the ABC1 transporter, impair leukemia self-renewal and sensitize AML progenitors to antineoplastics. Blood 1998; 92 (Suppl. 1): 675a.
38. Lehne G, De Angelis P, den Boer M, Rugstad HE. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia 1999; 13: 768-778.
39. Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 1999; 86: 300-311.
40. Cabot MC, Giuliano AE, Han TY, Liu YY. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res 1999; 59: 880-885.
41. Azare J, Pankova-Kholmyansky I, Salnikow K, Cohen D, Flescher E. Selective susceptibility of transformed T lymphocytes to induction of apoptosis by PSC 833, an inhibitor of P-glycoprotein. Oncol Res 2000; 12: 315-323.
42. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
43. Waldner CI, Mongini C, Alvarez E, Sanchez Lockhart M, Gravisaco MJ, Hajos SE. Interleukin 2 exerts autocrine stimulation on murine T-cell leukaemia growth. Br J Cancer 1997; 75: 946-950.
44. Duprez V, Lenoir G, Dautry-Varsat A. Autocrine growth stimulation of a human T-cell lymphoma line by interleukin 2. Proc Natl Acad Sci USA 1985; 82: 6932-2936.
45. Chen YZ, Gu XF, Caen JP, Han ZC. Interleukin-3 is an autocrine growth factor of human megakaryoblasts, the DAMI and MEG-01 cells. Br J Haematol 1994; 88: 481-487.
46. Zhu YM, Bradbury DA, Keith FJ, Russell N. Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia 1994; 8: 1982-1988.
47. Paul CC, Mahrer S, McMannama K, Baumann MA. Autocrine activation of the IL-3/GM-CSF/IL-5 signaling pathway in leukemic cells. Am J Hematol 1997; 56: 79-85.
48. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996; 274: 1855-1859.
49. Smyth MJ, Obeid LM, Hannun YA. Ceramide: a novel lipid mediator of apoptosis. Adv Pharmacol 1997; 41: 133-154.
50. Cabot MC, Han TY, Giuliano AE. The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation. FEBS Lett 1998; 431: 185-188.
51. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996; 14: 610-618.
52. De Lord C, Clutterbuck R, Titley J, Ormerod M, Gordon-Smith T, Millar J, Powles R. Growth of primary human acute leukemia in severe combined immunodeficient mice. Exp Hematol 1991; 19: 991-993.
53. Sawyers CL, Gishizky ML, Quan S, Golde DW, Witte ON. Propagation of human blastic myeloid leukemias in the SCID mouse. Blood 1992; 79: 2089-2098.
54. Beran M, Pisa P, Kantarjian H, Porwit A, Bjorkholm M. Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice. Hematol Pathol 1994; 8: 135-154.
55. Dick JE, Sirard C, Pflumio F, Lapidot T. Murine models of normal and neoplastic human haematopoiesis. Cancer Surv 1992; 15: 161-181.
56. Kamel-Reid S, Letarte M, Sirard C, Doedens M, Grunberger T, Fulop G, Freedman MH, Phillips RA, Dick JE. A model of human acute lymphoblastic leukemia in immune-deficient SCID mice. Science 1989; 246: 1597-1600.
57. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, Leiter EH. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154: 180-191.
58. Binder C, Tiemann M, Haase D, Humpe A, Kneba M. Isolated meningeal chloroma (granulocytic sarcoma) - a case report and review of the literature. Ann Hematol 2000; 79: 459-462.